Genetic Longevity, Ashkenazi Centenarians, and Indefinite Life Extension
Author(s): Scott Douglas Jacobsen
Publication (Outlet/Website): Personal SubStack
Publication Date (yyyy/mm/dd): 2026/06/02
Scott Douglas Jacobsen and Rick Rosner discuss exceptional longevity, focusing on Ashkenazi Jewish centenarian genetics, HDL particle size, IGF-1 receptor variants, and delayed age-related disease. They compare genetic protection with lifestyle and epigenetic effects, weighing nature against modern public health gains such as vaccination, sanitation, and medical care. Rosner links longevity science to Aubrey de Grey’s damage-repair framework, Ray Kurzweil’s indefinite life extension, and future human-technology integration under modern conditions.
Scott Douglas Jacobsen: Dr. Nir Barzilai is leading an effort to recruit 10,000 people aged 95 and older, along with their families, to study genetic factors associated with exceptional longevity. His research focuses on gene variants that may help protect against age-related diseases, including cardiovascular disease, Alzheimer’s disease, type 2 diabetes, and cancer.
He has been doing this work for some time. In studies of Ashkenazi Jewish centenarians and their families, researchers have found several genetic variants associated with exceptional longevity. Some of these are linked to favorable lipid profiles, including higher HDL cholesterol levels and larger HDL particle sizes.
Researchers have also studied variants in the IGF-1 receptor gene. These variants may reduce sensitivity to insulin-like growth factor signaling, a pathway associated with growth, metabolism, and aging. Similar pathways have been shown to influence lifespan in animal models, although the effects in humans are more complex.
One striking finding is that many of these centenarians did not necessarily follow unusually healthy lifestyles. Some were overweight, smoked, drank alcohol, or did not exercise regularly. Even so, they lived to very old ages, suggesting that protective genetic factors may have delayed the onset of age-related disease.
That is what I wanted to bring into the discussion. These individuals do not appear to avoid the major diseases of aging entirely; rather, they often develop them later than average. Their genes may give them additional healthy years before those diseases appear. Looking at the role of genetics in exceptional longevity, what are your thoughts on this?
Rick Rosner: I want to live long enough for science to replicate some of this so that I can gain extra years. Things are progressing reasonably quickly.
Aubrey de Grey has argued that aging involves seven broad categories of cellular and molecular damage. The question is whether fixing some of them would give people an additional 15 or 20 years, or whether all seven would need to be addressed. If all seven could be addressed, could that provide 40 or 50 extra years?
And if you gained 40 or 50 extra years, perhaps the advances made during that time could provide another 30 years, and so on. That is the idea behind indefinite life extension. Ray Kurzweil says you do not have to live forever; you only have to live indefinitely, because forever is a mathematical absurdity.
Jacobsen: Biologically, too.
Rosner: Yes. At some point, you are no longer entirely biological. You become merged with technologies or other systems.
Jacobsen: Do you think it was wise to use the Ashkenazi Jewish population for this research? Because kinship ties and marriage have historically tended to remain within the group, researchers may have considered it useful as a relatively genetically homogeneous founder population.
Rosner: They have a fairly tight genetic cluster. The strategy was probably to work with a relatively concentrated set of genomes. As homogeneous as the Ashkenazi Jewish population is, there is still considerable genetic variation, but not as much as in the general population. I am sure that gave him a useful amount of genetic diversity, enough to identify supercentenarians, but not so much that the signal would be lost in the variation. So, yes, I assume that was part of the strategy.
Jacobsen: Do you think that if researchers studied epigenetic factors in addition to genetics, they would find subtler effects or more profound effects?
Rosner: If you are looking at people who live 20 or 30 years longer than average, you can estimate the magnitude of the effect from the lifespan difference itself. I would not expect epigenetic effects alone to account for an additional 20 or 30 years of life. Living a healthy lifestyle, with regular exercise, a balanced diet, and other beneficial habits, might add several years, perhaps even a decade or more.
However, these researchers have identified genetic factors that appear to confer substantial advantages independently of lifestyle. A healthy lifestyle combined with favorable genetics may provide additional benefits, but the genetics seem to be doing much of the work that healthy habits only partially accomplish. So, no, I do not think the epigenetic effects associated with lifestyle are as influential as the underlying genetic factors in these cases.
Jacobsen: Would it be fair to argue that, in this context, nature is more influential than lifestyle?
Rosner: Under modern conditions, probably yes. That said, modern conditions themselves matter enormously. Public health measures such as vaccination, sanitation, and improved medical care have likely added decades to average life expectancy. Before widespread vaccination and sanitation, infant and childhood mortality were dramatically higher.
So, in a modern society where people are vaccinated, use seatbelts, and generally avoid major health risks such as smoking, genetics may become a more prominent factor in explaining differences in lifespan.
Jacobsen: Thank you very much for the opportunity and your time, Rick.
Last updated May 3, 2025. These terms govern all In-Sight Publishing content—past, present, and future—and supersede any prior notices. In-Sight Publishing by Scott Douglas Jacobsen is licensed under a Creative Commons BY‑NC‑ND 4.0; © In-Sight Publishing by Scott Douglas Jacobsen 2012–Present. All trademarks, performances, databases & branding are owned by their rights holders; no use without permission. Unauthorized copying, modification, framing or public communication is prohibited. External links are not endorsed. Cookies & tracking require consent, and data processing complies with PIPEDA & GDPR; no data from children < 13 (COPPA). Content meets WCAG 2.1 AA under the Accessible Canada Act & is preserved in open archival formats with backups. Excerpts & links require full credit & hyperlink; limited quoting under fair-dealing & fair-use. All content is informational; no liability for errors or omissions: Feedback welcome, and verified errors corrected promptly. For permissions or DMCA notices, email: scott.jacobsen2025@gmail.com. Site use is governed by BC laws; content is “as‑is,” liability limited, users indemnify us; moral, performers’ & database sui generis rights reserved.
